Literature DB >> 29222303

Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease.

Susanna Curtis1, Amanda M Brandow2,3.   

Abstract

Case 1: A 33-year-old man with hemoglobin SS (homozygous hemoglobin S) disease presents for his regular clinic visit. He had 6 hospital admissions for pain over the past year. He also has avascular necrosis of the right hip. He takes daily hydroxyurea with hematologic changes indicative of compliance. He also takes morphine sustained release twice daily and morphine immediate release every 6 hours as needed for pain. He feels that more optimal pain control at home would help him reduce his number of hospital admissions in the upcoming year and improve his daily functioning at home. His hematologist decides to use Patient-Reported Outcome Measurement Information System (PROMIS) and Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-ME) to follow changes in the patient's pain. Case 2: An 11-year-old girl with hemoglobin SS disease presents with her mother for her regular clinic visit. She had 2 admissions for pain over the past year. Her mother is concerned because she has been participating less in activities she previously enjoyed and missing classes to go to the school nurse because of pain. She is currently taking hydroxyurea and uses ibuprofen for pain. Her doctor prescribes morphine for home use but wants a way to measure if it is effective in improving her pain. Thus, her physician decides to use PROMIS and the Pediatric Quality of Life Inventory SCD (PedsQL SCD) module to determine the effectiveness of her pain control.
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29222303      PMCID: PMC6142574          DOI: 10.1182/asheducation-2017.1.542

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  12 in total

1.  GRADE guidelines: 3. Rating the quality of evidence.

Authors:  Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

2.  The number of people with sickle-cell disease in the United States: national and state estimates.

Authors:  David C Brousseau; Julie A Panepinto; Mark Nimmer; Raymond G Hoffmann
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

3.  Sickle-cell pain: advances in epidemiology and etiology.

Authors:  Wally R Smith; Marshall Scherer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

4.  Initial Evaluation of the Pediatric PROMIS® Health Domains in Children and Adolescents With Sickle Cell Disease.

Authors:  Carlton Dampier; Vaughn Barry; Heather E Gross; Yang Lui; Courtney D Thornburg; Darren A DeWalt; Bryce B Reeve
Journal:  Pediatr Blood Cancer       Date:  2016-02-19       Impact factor: 3.167

5.  PedsQL™ sickle cell disease module: feasibility, reliability, and validity.

Authors:  Julie A Panepinto; Sylvia Torres; Cristiane B Bendo; Timothy L McCavit; Bogdan Dinu; Sandra Sherman-Bien; Christy Bemrich-Stolz; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2013-02-25       Impact factor: 3.167

6.  Psychosocial and behavioral outcomes in children with sickle cell disease and their healthy siblings.

Authors:  Jeffrey I Gold; Nicole E Mahrer; Marsha Treadwell; Lina Weissman; Elliott Vichinsky
Journal:  J Behav Med       Date:  2008-09-11

7.  A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.

Authors:  David C Brousseau; J Paul Scott; Oluwakemi Badaki-Makun; Deepika S Darbari; Corrie E Chumpitazi; Gladstone E Airewele; Angela M Ellison; Kim Smith-Whitley; Prashant Mahajan; Sharada A Sarnaik; T Charles Casper; Lawrence J Cook; J Michael Dean; Julie Leonard; Monica L Hulbert; Elizabeth C Powell; Robert I Liem; Robert Hickey; Lakshmanan Krishnamurti; Cheryl A Hillery; Mark Nimmer; Julie A Panepinto
Journal:  Blood       Date:  2015-07-31       Impact factor: 22.113

8.  Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks.

Authors:  San D Keller; Manshu Yang; Marsha J Treadwell; Ellen M Werner; Kathryn L Hassell
Journal:  Health Qual Life Outcomes       Date:  2014-08-22       Impact factor: 3.186

9.  Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me℠.

Authors:  San Keller; Manshu Yang; Marsha J Treadwell; Kathryn L Hassell
Journal:  Health Qual Life Outcomes       Date:  2017-06-02       Impact factor: 3.186

10.  Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module.

Authors:  Julie A Panepinto; J Paul Scott; Oluwakemi Badaki-Makun; Deepika S Darbari; Corrie E Chumpitazi; Gladstone E Airewele; Angela M Ellison; Kim Smith-Whitley; Prashant Mahajan; Sharada A Sarnaik; T Charles Casper; Larry J Cook; Julie Leonard; Monica L Hulbert; Elizabeth C Powell; Robert I Liem; Robert Hickey; Lakshmanan Krishnamurti; Cheryl A Hillery; David C Brousseau
Journal:  Health Qual Life Outcomes       Date:  2017-06-12       Impact factor: 3.186

View more
  4 in total

Review 1.  Neuropathic pain in sickle cell disease: measurement and management.

Authors:  Alexander Glaros; Amanda M Brandow
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.

Authors:  Arlene Smaldone; Deepa Manwani; Banu Aygun; Kim Smith-Whitley; Haomiao Jia; Jean-Marie Bruzzese; Sally Findley; Joshua Massei; Nancy S Green
Journal:  BMC Pediatr       Date:  2019-10-15       Impact factor: 2.567

3.  Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals With Sickle Cell Disease: Design and Feasibility Study.

Authors:  Lakshmanan Krishnamurti; Staci D Arnold; Ann Haight; Allistair Abraham; Gregory Mt Guilcher; Tami John; Nitya Bakshi; Shalini Shenoy; Karen Syrjala; Paul L Martin; Sonali Chaudhury; Gretchen Eames; Olusola Festus Olowoselu; Matthew Hsieh; Josu De La Fuente; Kimberly A Kasow; Elizabeth Stenger; Anne Mertens; Fuad El-Rassi; Peter Lane; Bronwen E Shaw; Lillian Meacham; David Archer
Journal:  JMIR Res Protoc       Date:  2022-07-06

4.  Health-related quality of life in hemoglobinopathies: A systematic review from a global perspective.

Authors:  Francesca Rodigari; Giorgia Brugnera; Raffaella Colombatti
Journal:  Front Pediatr       Date:  2022-08-25       Impact factor: 3.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.